Matrix Capital Management Company, LP's Form 4 filing
Zentalis Pharmaceuticals, Inc. (ZNTL) · filed Dec 15, 2025
- Accession no.
- 0000902664-25-005288
- Filed
- Dec 15, 2025, 5:24 PM ET
- Trade date
- Dec 15, 2025
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market sales total $9.97M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Matrix Capital Management Company, LPCIK 0001410830 | 10% Owner |
| Goel David E.CIK 0001548144 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 15, 2025 | Common Stock, par value $0.001 per share | SSaleDisposed | −7,500,000 | $1.33 | −$9,975,000 | 6,459,973 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.